On October 8, 2026, international hematology panels reaffirmed Polivy® (Polatuzumab vedotin-piiq 140 mg and 30 mg powder for concentrate for solution for infusion) by Roche / Genentech as the first targeted therapy in over two decades to significantly improve progression-free survival in newly diagnosed diffuse large B-cell lymphoma (DLBCL). By replacing vincristine in the historical R-CHOP regimen, the Pola-R-CHP protocol delivers the potent microtubule disruptor monomethyl auristatin E (MMAE) directly into malignant CD79b-expressing B-cells, transforming cure rates for high-risk lymphoma patients.

Through Onco Medicine, certified genuine Roche packs of Polivy Polatuzumab Vedotin 140mg & 30mg Injection are supplied to hospital oncology departments, practicing oncologists, and named patients globally via GDP-certified 2°C–8°C thermal transit with full Certificate of Analysis (COA) batch release.

Mechanism of Action: CD79b Targeting & Targeted Microtubule Disruption

Polatuzumab vedotin is an engineered antibody-drug conjugate engineered for targeted B-cell eradication:

• Targeted Monoclonal Antibody: Recombinant humanized IgG1 antibody that binds selectively to the extracellular domain of CD79b, a component of the B-cell receptor complex expressed ubiquitously on normal and malignant B-cells, including >95% of DLBCL tumors.
• Cleavable Peptide Linker: Stable maleimidocaproyl-valine-citrulline protease-cleavable linker designed to maintain circulating stability until internalization.
• Potent Cytotoxic Payload: Monomethyl auristatin E (MMAE). Following receptor-mediated endocytosis and lysosomal cleavage, intracellularly released MMAE binds tubulin, halts mitotic spindle formation, induces G2/M phase cell cycle arrest, and triggers apoptotic cellular demise.
• Targeted Delivery vs. Vincristine: By substituting systemic vincristine with antibody-directed MMAE, the Pola-R-CHP regimen maximizes anti-lymphoma cytotoxicity while avoiding the severe non-targeted neurotoxicities typical of vinca alkaloids.

The Landmark POLARIX Phase 3 Evidence

The practice-changing Phase 3 POLARIX trial evaluated Pola-R-CHP against standard R-CHOP in frontline intermediate- and high-risk DLBCL:

• Progression-Free Survival Advantage: Pola-R-CHP demonstrated a statistically significant 27% reduction in the risk of disease progression, relapse, or death compared to standard-of-care R-CHOP (hazard ratio 0.73).
• Subgroup Consistency: Prolonged PFS benefits were observed across key high-risk clinical subsets, including elderly patients (age >60), patients with elevated IPI scores (3–5), and both activated B-cell (ABC) and germinal center B-cell (GCB) subtypes.
• Relapse-Free Survival: Substantially lowered the need for secondary salvage therapies, autologous stem cell transplantation (ASCT), and CAR-T cell infusions.

Dosing Protocols & Toxicity Management Standards

Administration protocols require adherence to standardized infusion schedules:

• Recommended Dosage: Administered as an intravenous infusion at 1.8 mg/kg every 21 days for 6 cycles in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP).
• Infusion Times: The initial infusion is administered over 90 minutes. Subsequent infusions may be administered over 30 minutes if previous infusions were well tolerated.
• Peripheral Neuropathy Surveillance: Sensory and motor neuropathy must be monitored prior to each cycle. Dose reductions to 1.4 mg/kg or 1.0 mg/kg are indicated for Grade 2 neuropathy; therapy is discontinued for persistent Grade 3 neuropathy.
• Infection Prophylaxis: Patients with high risk of neutropenic fever should receive prophylactic G-CSF and antimicrobial coverage during cycles.

Global Cold-Chain Sourcing via Onco Medicine

For international healthcare providers, oncology pharmacies, and named patients navigating domestic supply shortages or formulary delays, Onco Medicine facilitates rapid, legally compliant cross-border procurement of genuine Roche Polivy:

• Authorized Import Pathways: Managed under US FDA Personal Importation Policy (PIP), UK MHRA Named-Patient Import, Australian TGA Special Access Scheme (SAS), Brazilian ANVISA RDC import exemptions, and Middle East MOHAP authorizations.
• Uncompromising Cold-Chain (2°C–8°C): Shipped in validated thermal packaging with continuous digital temperature data loggers to ensure biological integrity from dispatch to clinic receipt within 4 to 8 business days worldwide.
• Full Batch Authentication: Supplied in original tamper-evident cartons accompanied by official batch test reports and Certificates of Analysis.

Contact our lymphoma and hematology desk for institutional pricing, batch availability, and expedited international shipping: support@onco-medicine.com or message our clinical pharmacists on WhatsApp (+91 94275 19809).